The Experts below are selected from a list of 23217 Experts worldwide ranked by ideXlab platform
Derkjan Dijk - One of the best experts on this subject based on the ideXlab platform.
-
a method to assess the dissipation of the corrected residual effects of corrected hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
-
a method to assess the dissipation of residual hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026). © 2012 Lippincott Williams & Wilkins.
Julia Boyle - One of the best experts on this subject based on the ideXlab platform.
-
a method to assess the dissipation of the corrected residual effects of corrected hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
-
a method to assess the dissipation of residual hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026). © 2012 Lippincott Williams & Wilkins.
Jenny Scott - One of the best experts on this subject based on the ideXlab platform.
-
a method to assess the dissipation of the corrected residual effects of corrected hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
-
a method to assess the dissipation of residual hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026). © 2012 Lippincott Williams & Wilkins.
Carol Rockett - One of the best experts on this subject based on the ideXlab platform.
-
a method to assess the dissipation of the corrected residual effects of corrected hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
-
a method to assess the dissipation of residual hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026). © 2012 Lippincott Williams & Wilkins.
Giuseppe Atzori - One of the best experts on this subject based on the ideXlab platform.
-
a method to assess the dissipation of the corrected residual effects of corrected hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026).
-
a method to assess the dissipation of residual hypnotics eszopiclone versus zopiclone
Journal of Clinical Psychopharmacology, 2012Co-Authors: Julia Boyle, John A Groeger, Walter Paska, James A Cooper, Carol Rockett, Sion Jones, Paul Gandhi, Jenny Scott, Giuseppe Atzori, Derkjan DijkAbstract:Next-day residual effects of single evening doses of 3 mg of eszopiclone, 7.5 mg of zopiclone, and placebo were assessed in a randomized, double-blind, placebo-controlled, 3-way crossover study that used a mild sleep restriction protocol (sleep duration, 7 hours). During each period, 91 healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion Task, Digit Symbol Substitution Test, N-back Tasks, and Linear Analogue Rating Scales every half-hour from 7.5 to 11.5 hours after dose, commencing 15 minutes after awakening. Nighttime dosing of both eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance impairment, and these residual effects dissipated over time. Eszopiclone did not differ from zopiclone on the primary end point, mean Continuous Tracking Test tracking error averaged from 7.5 to 9.5 hours after dose; however, a prespecified post hoc parametric analysis of reciprocal-transformed data favored eszopiclone over racemic zopiclone (P = 0.026). © 2012 Lippincott Williams & Wilkins.
